Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
doi:10.1016/j.cca.2007.09.019
Making that choice safely and effectively requires more than general information
Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten
In agreement with expectations, the first outcome trial of a GLP-1RA, the ELIXA trial of the short-acting lixisenatide, an exendin-4 derivative with properties almost identical to those of exendin-4 or exenatide (stable, full agonists of the GLP-1 receptor), showed no increased cardiovascular risk in a patient group with severely increased CVD risk
US$ 23.32
US$ 21.59
US$ 23.62
US$ 21.39
US$ 24.72
US$ 25.43
US$ 27.69
US$ 26.50
